Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer

Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer

Intravesical BCG is active against non-muscle invasive bladder cancer (NMIBC), but bladder cancer will recur and even progress in a significant number of patients. To improve the response rate, N-803, an IL-15 superagonist was administered in combination with BCG. To evaluate the safety and efficacy...

Full description

Bibliographic Details
Main Authors: Charles J. Rosser, Sergei Tikhonenkov, Jeffrey W. Nix, Owen T.M. Chan, Irina Ianculescu, Sandeep Reddy, Patrick Soon-Shiong
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
non-muscle invasive bladder cancer
il15
bcg
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1912885

Internet

http://dx.doi.org/10.1080/2162402X.2021.1912885

Similar Items